Oric Pharmaceuticals (ORIC) Expected to Release Quarterly Earnings on Thursday

Oric Pharmaceuticals (NASDAQ:ORIC) is expected to post its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect the company to announce earnings of ($0.3861) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 20, 2026 at 4:00 PM ET.

Oric Pharmaceuticals Price Performance

Oric Pharmaceuticals stock opened at $8.91 on Wednesday. Oric Pharmaceuticals has a one year low of $7.23 and a one year high of $14.68. The business has a fifty day moving average of $11.82 and a two-hundred day moving average of $11.06.

Insider Transactions at Oric Pharmaceuticals

In other Oric Pharmaceuticals news, CFO Dominic Piscitelli sold 14,000 shares of the firm’s stock in a transaction dated Tuesday, October 20th. The stock was sold at an average price of $13.53, for a total value of $189,420.00. Following the sale, the chief financial officer directly owned 69,828 shares of the company’s stock, valued at approximately $944,772.84. This trade represents a 16.70% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 105,000 shares of company stock valued at $1,432,952. 5.70% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on ORIC shares. BTIG Research restated a “buy” rating and set a $26.00 target price on shares of Oric Pharmaceuticals in a research report on Wednesday, October 28th. Leerink Partners started coverage on shares of Oric Pharmaceuticals in a report on Monday, October 5th. They issued an “outperform” rating and a $26.00 price target on the stock. HC Wainwright increased their price target on shares of Oric Pharmaceuticals from $25.00 to $27.00 and gave the company a “buy” rating in a research report on Monday, August 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Oric Pharmaceuticals in a research note on Thursday, October 15th. Finally, Stifel Nicolaus raised their price objective on shares of Oric Pharmaceuticals from $14.00 to $18.00 and gave the stock a “buy” rating in a research note on Monday, October 26th. Fourteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $21.25.

About Oric Pharmaceuticals

Oric Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its research centers on therapies intended to address treatment resistance and improve outcomes for people with tumors that have become difficult to treat. The company’s drug candidates have included ORIC-114, a targeted therapy designed to inhibit EGFR and HER2 alterations, and ORIC-944, which targets the PRC2 pathway and has been investigated for prostate cancer. These programs are investigational and are not approved medicines.